Home / Letter From The Editor

Letter From The Editor

July 16, 2019

Marian Ayad, our current PharmD candidate from University of Colorado, was questioning whether waiting till a patient was in their 30’s or 40’s was the best for performing gastric bypass. When she did her research she found out that the sooner the bypass is done, the better the outcomes, especially …

Read More »

July 13, 2019

There are a lot of direct to consumer ads on TV these days. There is a lot of cultural diversity in the patients portrayed, and that lends itself to the assumption that these medications have the same effects across all racial segments. When you look deeper into the studies you …

Read More »

July 9, 2019

Have you ever heard the old saying; “if it looks like a duck and quacks like a duck, then it must be a duck”? Well, this week Kassey James, our Pharm.D. Candidate from LECOM School of Pharmacy, brings us an article that proves that this is not always true. She …

Read More »

July 6, 2019

I recently gave up my cable TV and DVR, and in order to get network channels I put a paper-thin HD antenna on my window to get them for free. The downside is that I sometimes have to watch commercials. I know that January is when all the fitness experts …

Read More »

July 2, 2019

Thirty years ago most patients with type 2 diabetes did not develop the disease until they were in their late 60’s. They often did not develop the cardiovascular or kidney problems that we are so worried about today. This was likely due to their advanced age at diagnosis and a …

Read More »

June 29, 2019

Last week our intern Marian Ayad, BSPharm, PharmD candidate, University of Colorado, was talking to me about the problems that occur when there is a lower age limit on the use of a medication. She had been reviewing PI’s on various diabetes medications and constantly found that most of them …

Read More »

June 25, 2019

This is the last week that Emma Kammerer, L|E|C|O|M Bradenton School of Pharmacy, PharmD Candidate will be with us on her rotation. One of the topics we discussed was how to preserve beta cell function by starting aggressive management from day one. Like many pharmacists she was somewhat surprised by …

Read More »

June 22, 2019

For many years the Holy Grail of diabetes therapy has been oral insulin. The thought process has been: if patient did not have to inject, they would be happy to use insulin multiple times a day. While we don’t seem that close to oral insulin, we do have an opportunity …

Read More »

June 18, 2019

Our good friend — and gadget wearing friend — from Diabetic Investor, David Kliff, was at the recent ADA Scientific Sessions and he was talking about TIR. This is the new standard for measuring control of insulin-using diabetes patients. For those of you who don’t know, TIR means “time in …

Read More »

June 15, 2019

When my wife was first diagnosed with diabetes we immediately started her on long acting insulin and the GLP-1 agonist Trulicity. I believe that the use of these 2 meds prolonged her insulin producing capacities for 3 years before the antibodies won out. This week we have a report from …

Read More »